Physician profile
Joseph E Weatherly
NPI 1417392697
$1,516.39
in general payments reported to CMS, 2019-2025
25 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $132 · 2021: $50.04 · 2022: $29.81 · 2023: $87.67 · 2024: $516 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $997.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $317.50 | 2019-2025 | |
| Ucb, INC. | $192.52 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $162.95 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $104.40 | 2019-2025 | Eliquis |
| Abbvie INC. | $96.48 | 2023-2024 | Vraylar |
| Phathom Pharmaceuticals, INC. | $89.99 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $66.54 | 2024-2025 | Verquvo |
| Philips North America LLC | $60.14 | 2024-2025 | Mcot, (Ck4) Mcot |
| Amgen INC. | $53.01 | 2019 | |
| Celgene Corporation | $46.05 | 2023-2024 | Zeposia, Orencia |
| Janssen Pharmaceuticals, INC | $34.71 | 2021-2023 | Xarelto |
| Nevro Corp. | $34.57 | 2019 | |
| Pfizer INC. | $32.46 | 2019-2022 | |
| Viatris Specialty LLC | $32.34 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.58 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.80 | 2025 | Entyvio |
| Scilex Pharmaceuticals INC. | $21.30 | 2020 | |
| Inspire Medical Systems, INC. | $16.73 | 2024 | Inspire |
| Fidia Pharma USA INC. | $16.66 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $16.19 | 2024 | Arcalyst |
| Boston Scientific Corporation | $15.19 | 2025 | Watchman Flx |
| Ultragenyx Pharmaceutical INC. | $15.07 | 2022 | |
| Glaxosmithkline, LLC. | $12.31 | 2019 | |
| Lilly USA, LLC | $12.27 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Weatherly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.